Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

NOP agonist AT-312 can reduce alcohol reward

Feb. 26, 2018

Pain Therapeutics resubmits Remoxy ER NDA

Feb. 14, 2018

Opiant Pharmaceuticals announces plans for intranasal nalmefene

Feb. 13, 2018

V1B receptor antagonism may enhance alcohol dependency treatment

Feb. 6, 2018

Achieve Life Sciences amends technology license agreement with University of Bristol

Jan. 25, 2018

AP-202 shows promise as an agent for nicotine addiction

Jan. 23, 2018

FDA issues complete response letter for CAM-2038 NDA for opioid use disorder

Jan. 22, 2018

Mosedipimod receives FDA orphan drug designation for ARS

Jan. 5, 2018

Addex and Indivior sign licensing and collaboration agreement for ADX-71441 to treat addiction

Jan. 3, 2018

Axsome Therapeutics and Duke University to collaborate on phase II study of AXS-05

Dec. 15, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...